About
Drugs blocking the interaction between the ligand and its Dependence Receptor
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibody
Team (3)
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
1
As Collaborator
6
Total Enrollment
518
By Phase
PHASE1: 4PHASE1/PHASE2: 2PHASE2: 1
By Status
ACTIVE_NOT_RECRUITING: 2RECRUITING: 2NOT_YET_RECRUITING: 1TERMINATED: 1COMPLETED: 1
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06203821Collaborator
Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer
PHASE1Not yet recruiting
25 participants
Started: Sep 1, 2025 · Completed: Dec 31, 2027
NCT06150040Collaborator
Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]
PHASE1/PHASE2Terminated
1 participants
Started: Sep 11, 2024 · Completed: Feb 18, 2025
NCT05546853Collaborator
Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma
PHASE1Active, not recruiting
43 participants
Started: Mar 28, 2023 · Completed: Jun 16, 2025
NCT05546879Collaborator
Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC
PHASE1Recruiting
52 participants
Started: Mar 15, 2023 · Completed: Mar 15, 2027
NCT05605496Collaborator
NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies
PHASE2Recruiting
87 participants
Started: Jan 6, 2023 · Completed: Nov 24, 2026
Locations (1)
Headquarters
Lyon, France
Map
Loading map...